Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab.

UnknownOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

October 7, 2021

Primary Completion Date

December 15, 2024

Study Completion Date

December 15, 2024

Conditions
Acute GastritisChronic Gastritis
Interventions
DRUG

Mucosta®SR Tablets 150mg(Rebamipide)

adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.

Trial Locations (1)

Unknown

RECRUITING

Soon Chun Hyang University Hospital Seoul, Seoul

All Listed Sponsors
lead

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY